With the accreditation, the La Jolla, California-based molecular dermatology firm can provide its services in all 50 states and the District of Columbia.
The genetic testing firm can now offer its Prelude noninvasive prenatal test to residents in New York State.
The firm recently won $4.5 million as well as approval for its Fertilome test from New York state, though some have questioned the test's clinical utility.
The test, which also is FDA-approved, can be used to identify best responders to three non-small cell lung cancer treatment regimens.
The firm has secured NYS approval for its sequencing-based 32-gene Fertilome assay, which it originally launched in January.
Interpace can now offer the new service alone or in conjunction with ThyGenX next-generation sequencing oncogene panel in New York.
The agency said that its action on MSK IMPACT "advances a policy framework that paves the way for the efficient review and availability of other NGS-based cancer profiling tools."
The test is performed on the company's AmpiProbe platform, and the approval expands Enzo's offering of infectious disease tests in New York.
The New York State Clinical Laboratory Evaluation Program has approved the company's FoundationACT blood-based circulating tumor DNA assay.
The firm said it will offer 25 million units consisting of common stock and common warrants at $.40 per unit.